Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
---|---|---|---|---|---|---|
Taro Pharmaceutical | Warfarin | Warfarin | 1999-07-15 | |||
LEO Pharma | Tinzaparin | Innohep | 2000-07-14 | |||
Mylan | Apixaban | Apixaban | 2019-12-23 | |||
Fondaparinux | Arixtra | 2001-12-07 | ||||
Heparin | Heparin | 2017-11-30 | ||||
Rivaroxaban | Rivaroxaban Viatris (previously Rivaroxaban Mylan) | 2021-11-12 | ||||
Dabigatran etexilate | Dabigatran Etexilate | 2025-02-03 | ||||
Johnson & Johnson | Rivaroxaban | Xarelto | 2024-08-28 | 2011-07-01 | $2,373 M | Y2024 |
GSK | Fondaparinux | Quixidar | 2002-03-21 | |||
Cipla | Warfarin | Warfarin | 2011-05-25 | |||
Sandoz | Enoxaparin | Enoxaparin | 2010-07-23 | |||
Heparin | Heparin | 2011-06-08 | ||||
Boehringer Ingelheim | Dabigatran etexilate | Pradaxa | 2023-06-14 | 2010-10-19 | ||
Aspen Global | Heparin | Liquaemin | 1982-01-01 | |||
Organon | Phenprocoumon | Liquamar | 1982-01-01 |
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
---|---|---|---|---|---|